Valuation: NEOVACS SA

Market Cap 4.09T 4.77T 3.83T 3.5T 6.6T 5L 6.67T 45.26T 17.6T 2L 17.91T 17.53T 8L P/E 2023 *
-
P/E 2024 -
Enterprise Value -2L -2L -2L -2L -3L -2.25Cr -3L -22.25L -9L -1.13Cr -9L -9L -3.73Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1L
+0.75%+4.56%+3.28%+24.99% 5.12TCr
+1.01%-0.20%+471.68%+564.93% 4.53TCr
+0.16%+7.88%+36.14%+20.76% 4.28TCr
-0.66%+2.61%+18.59%+87.04% 4.23TCr
+0.88%-3.48%+17.20%+53.83% 3.22TCr
-0.12%+3.84%+33.73%+145.25% 1.73TCr
-0.53%+1.84% - - 1.65TCr
+0.49%+5.68%+10.31%+31.79% 1.48TCr
+1.15%+4.17%+84.49%+50.33% 1.43TCr
Average +0.34%+3.23%+84.43%+122.36% 3.08TCr
Weighted average by Cap. +0.37%+3.07%+101.40%+141.80%

Financials

2023 2024
Net sales 5L 6L 5L 5L 9L 5.96Cr 9L 59.05L 22.96L 2.99Cr 23.37L 22.86L 9.9Cr 4L 5L 4L 4L 7L 4.85Cr 7L 48.04L 18.68L 2.43Cr 19.01L 18.6L 8.06Cr
Net income -87.43L -1.02Cr -81.8L -74.78L -1.41Cr -98Cr -1.43Cr -9.68Cr -3.76Cr -49Cr -3.83Cr -3.75Cr -162.3Cr -3.29Cr -3.84Cr -3.08Cr -2.82Cr -5.31Cr -367.75Cr -5.37Cr -36Cr -14Cr -184.66Cr -14Cr -14Cr -610.98Cr
Net Debt -2L -3L -2L -2L -4L -2.64Cr -4L -26.18L -10.18L -1.33Cr -10.36L -10.14L -4.39Cr -2L -2L -2L -2L -3L -2.29Cr -3L -22.7L -9L -1.15Cr -9L -9L -3.81Cr
Logo NEOVACS SA
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-